ECOR - NASDAQ
electroCore, Inc.
$9.75
-1.1%electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
At a Glance
Live SnapshotelectroCore, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
Working Capital
Positive working capital, but relatively tight. The company should monitor cash flow carefully.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
electroCore, Inc. Balance Sheet
ECOR • NASDAQ
| electroCore, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
7M | 3.5M | 10.3M | 17.7M | 34.7M | 4.2M | 13.6M | 7.6M | 13.2M | 416.3K | |
4.6M | 8.5M | 0.0 | 0.0 | 0.0 | 18.4M | 10.5M | 61M | 24M | 0.0 | |
11.6M | 12M | 10.3M | 17.7M | 34.7M | 22.6M | 24.1M | 68.6M | 37.2M | 416.3K | |
1M | 1.4M | 717K | 401K | 438K | 270.5K | 496.1K | 267.6K | 103.2K | 24.7K | |
1M | 1.4M | 717K | 401K | 438K | 270.5K | 496.1K | 267.6K | 103.2K | 24.7K | |
1.6M | 1.7M | 2.2M | 2M | 1.4M | 876.4K | 911.2K | 1.9M | 327.8K | 48.5K | |
0.0 | 0.0 | 0.0 | 0.0 | 1.1M | 1.3M | 1.1M | 1.9M | 570.8K | 16.4K | |
-2.7M | 1.3M | 1.1M | 1.1M | -572.0 | 0.0 | -20.2K | 1.9M | 856.9K | 16.4K | |
11.6M | 16.3M | 14.3M | 21.2M | 37.5M | 25.1M | 26.5M | 72.7M | 39M | 505.9K | |
NON-CURRENT ASSETS | ||||||||||
0.0 | 3.9M | 706K | 615K | 760K | 761.3K | 1.8M | 380.9K | 168.6K | 48.4K | |
7.1M | 274K | 1.1M | 3M | 4.5M | 5.7M | 7.2M | 424.9K | 30.6K | 67.7K | |
7.1M | 4.2M | 1.8M | 3.6M | 5.3M | 6.5M | 8.9M | 805.8K | 199.3K | 116.1K | |
18.7M | 20.5M | 16.1M | 24.8M | 42.8M | 31.5M | 35.5M | 73.5M | 39.2M | 622K | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
2.7M | 2.2M | 2.4M | 2.3M | 1.2M | 2.3M | 5.2M | 2.7M | 840.4K | 2.5M | |
2.7M | 1.8M | 2.2M | 2.1M | 938K | 2.1M | 5.2M | 2.7M | 840.4K | 2.2M | |
0.0 | 382K | 272K | 133K | 263K | 243.2K | 0.0 | 0.0 | 0.0 | 226K | |
0.0 | 2.6M | 2.2M | 1.8M | 967K | 926.5K | 1.7M | 3.4M | 3M | 829.5K | |
375K | 0.0 | 0.0 | 0.0 | 0.0 | 311.4K | 111.9K | 0.0 | 0.0 | 0.0 | |
0.0 | 361K | 89K | 74K | 61K | 534.5K | 486.4K | 0.0 | 0.0 | 0.0 | |
0.0 | 382K | 272K | 133K | 263K | 243.2K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 78K | 245K | 152K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
8.3M | 3.9M | 3.1M | 2.8M | 3.3M | 1.8M | 1.6M | 948.6K | 2.2M | 838.8K | |
11.3M | 9.2M | 8.1M | 7M | 5.5M | 5.9M | 9.1M | 7.1M | 6.1M | 4.1M | |
NON-CURRENT LIABILITIES | ||||||||||
6.6M | 0.0 | 0.0 | 0.0 | 0.0 | 1.1M | 0.0 | 0.0 | 0.0 | 3.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 245.6K | 122.6M | 53.9M | |
9M | 3.8M | 537K | 625K | 700K | 2M | 1.4M | 245.6K | 122.6M | 57.5M | |
2.4M | 4.1M | 626K | 699K | 761K | 1.4M | 1.9M | 0.0 | 0.0 | 0.0 | |
20.4M | 12.9M | 8.7M | 7.7M | 6.2M | 7.9M | 10.6M | 7.3M | 128.7M | 61.7M | |
SHAREHOLDERS' EQUITY | ||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -22.6M | -8.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 73.5B | 122.3M | 53.5M | |
8K | 7K | 6K | 5K | 5K | 45.6K | 29.8K | 29.5K | 40.2M | 30.9M | |
189.2M | 184.5M | 172.7M | 163.5M | 160.8M | 130.2M | 107.8M | 103.8M | 22.6M | 8.1M | |
-191.1M | -177.1M | -165.2M | -146.4M | -124.2M | -107M | -83.5M | -38.3M | -152.9M | -100.7M | |
99K | 114K | -64K | -69K | 13K | -251.5K | -41.3K | 60.8K | 80.2K | 214K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -73.5B | -99.7M | -45.4M | |
-1.7M | 7.5M | 7.4M | 17.1M | 36.6M | 23M | 24.3M | 65.6M | -90.1M | -61.5M | |
-1.7M | 7.5M | 7.4M | 17.1M | 36.6M | 23.6M | 24.9M | 66.2M | -89.5M | -61.1M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 635.6K | 635.6K | 635.6K | 604.1K | 400.4K | |
SUMMARY | ||||||||||
18.7M | 20.5M | 16.1M | 24.8M | 42.8M | 31.5M | 35.5M | 73.5M | 39.2M | 622K | |
4.6M | 8.5M | 0.0 | 0.0 | 0.0 | 18.4M | 10.5M | 61M | 24M | 0.0 | |
9.4M | 4.1M | 626K | 699K | 761K | 2.8M | 2M | 0.0 | 0.0 | 3.7M | |
2.4M | 686K | -9.7M | -17M | -33.9M | -1.4M | -11.5M | -7.6M | -13.2M | 3.2M | |
7,994,444 | 7,994,444 | 7,994,444 | 7,994,444 | 7,994,444 | 7,994,444 | 7,994,444 | 7,994,444 | 7,994,444 | 7,994,444 |
SEC Filings
ECOR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 20, 2026 | January 20, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
S-3 S-3 N/A | October 03, 2025 | October 03, 2025 | ||
8-K 8-K 2025 N/A | October 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 03, 2025 | September 02, 2025 | 2025 |
Related Guides
Continue your ECOR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.